Pipeline
Trials
People
News
Contact
Contact
News
Button Text
February 15, 2024
OrphAI Therapeutics Receives Orphan Drug Designation for AIT-101 as a treatment for amyotrophic lateral sclerosis in the European Union
January 24, 2024
OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors
October 2, 2023
OrphAI Therapeutics Announces Oral Presentation and Posters at the 22nd Annual NEALS Conference
September 28, 2023
AI Therapeutics Announces Name Change to OrphAI Therapeutics
August 31, 2023
AI Therapeutics Announces Initiation of a Phase 2 Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
August 18, 2023
AI Therapeutics Announces Investigator Initiated Phase 2 Trial at UCSF to Study LAM-001 in Patients With Bronchiolitis Obliterans Syndrome (BOS) Post-Lung Transplant
July 12, 2023
AI Therapeutics Announces Appointment of Biotechnology Industry Leader David Scheer as Chairman of the Board of Directors
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of LAM-001 for Treatment of Pulmonary Arterial Hypertension (PAH)
May 9, 2023
AI Therapeutics Announces Poster Presentation at the 2023 American Thoracic Society International Conference
April 5, 2023
AI Therapeutics Announces Positive Results from Phase 2a Biomarker-driven Trial of AIT-101 in Patients with C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
April 25, 2022
AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
February 16, 2022
AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer
January 13, 2022
AI Therapeutics Announces Initiation of a Phase II Clinical Trial of AIT-101 for Treatment of ALS
